BRIEF—Accent raises $40 million to develop RNA-modifying technology

Massachusetts, USA-based oncology specialist Accent Therapeutics has raised $40 million in a series A financing round, with money coming from investors The Column Group, Atlas Venture and EcoR1 Capital.

The cash will be used to establish a discovery platform and pipeline of therapeutic candidates targeting RNA-modifying proteins (RMPs), a novel target space for precision cancer therapies.

Chief scientific officer Robert Copeland said: “Epitranscriptomics opens a rich new target space, including RMPs that are associated with specific cancers, many with poor patient prognoses.”

“We plan to treat patients by precisely targeting cancers that are uniquely dependent on these specific RMPs.”